• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Weekly, April 24, 2017

The CenterWatch Weekly, April 24, 2017

April 24, 2017
CenterWatch Staff

Big Tech takes a step forward as Verily unveils Study Watch

Verily Life Sciences, a subsidiary of Google’s parent company Alphabet, has unveiled a new smartwatch for clinical research that can capture round-the-clock health data for large-scale and long-term studies. Although the investigational device, called the Verily Study Watch, is not available for sale, Dutch researchers will use the health-tracking watch in a multi-year Parkinson’s disease study that will begin enrolling patients in July. In addition, Verily launched a four-year observational study last week with Duke University School of Medicine and Stanford Medicine that will use the Study Watch to track daily health data from some 10,000 volunteers.

Accelovance launches HERO to hone in on early phase cancer trials

Cancer is the therapeutic target of more than half of all clinical trials now, and yet, said Accelovance President and CEO Steve Trevisan, small companies trying to launch early phase trials on their promising young compounds in oncology have no good place to turn for quality handholding. That’s why the CRO Accelovance has launched HERO (Helping Early Research in Oncology), an initiative that Trevisan said is tightly tailored to the needs of small pharma companies and biotech firms working on the very early stages of cancer trials.

 

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing